抗IL-10 Receptor β抗体(Anti-IL-10 Receptor β, Human, Goat-Poly antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	Mouse myeloma cell line NS0-derived recombinant human IL-10 R beta Met20-Ser220Accession # Q08334
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Specificity	Detects human IL-10 R beta in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human(rh) IL‑20 R alpha, rhIL-10 R, and rhIL-20 R beta is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human IL‑10 R beta Fc Chimera (Catalog # 874-RB)
Flow Cytometry	2.5 µg/106 cells	Human whole blood monocytes
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Neutralization	Measured by its ability to neutralize IL‑10 R beta -mediated IL‑10 response in LPS-activated human peripheral blood mononuclear cells (PBMC). Ralph, P. et al. (1991) J. Immunology 148:808. The Neutralization Dose (ND50) is typically 2-6 µg/mL in the presence of 0.25 ng/mL Recombinant Human IL‑10 and 0.25 ng/mL LPS.

Neutralization

IL‑10 Inhibition of IL‑1 beta secretion and Neutralization by Human IL‑10 R beta  Antibody. Recombinant Human IL‑10 (Catalog # 217-IL) inhibits IL‑1 beta secretion in LPS-activated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line), as measured by the Human IL‑1 beta /IL‑1F2 Quantikine ELISA Kit (Catalog # DLB50).IL‑1 beta secretion inhibited by Recombinant Human IL‑10 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑10 R beta Antigen Affinity-purified Polyclonal Antibody (Catalog # AF874). The ND50 is typically 2-6 µg/mL in the presence of LPS (0.25 ng/mL).

目次に戻る

Related Product & Information

Long Name	Interleukin 10 Receptor beta
Entrez Gene IDs	3588 (Human); 16155 (Mouse)
Background	IL-10 R beta
background_content	Background: IL-10 R beta IL-10, also known as IL-10 R2, mediates its biological activities via binding to a heteromeric receptor complex consisting of two distinct type II cytokine receptor subunits, the ligand binding IL-10 R alpha and the IL-10 R beta which does not bind IL-10 by itself but is required for signal transduction. The cDNA for human IL-10 R beta encodes a 325 amino acid (aa) residue type I transmembrane precursor protein with a 20 aa signal sequence, a 200 aa extracellular region, a 29 aa transmembrane segment, and a short 76 aa cytoplasmic domain. Within the extracellular region, there are two 100 aa subdomains that resemble the constant region of immunoglobulins. This structural motif is responsible for the alternative designation of IL-10 R beta as CRF2-4 (the 4th member of the cytokine receptor family class II/2). Human and mouse IL-10 R beta share approximately 69% aa sequence identity. Binding of the non-covalent IL-10 dimer to two IL-10 R alpha chains recruits twoIL‑10 R beta chains resulting in the activation and phosphorylation of the signaling cascade involving JAK1, TYK2, and STAT3. IL-10 R beta  is expressed ubiquitously.IL‑10 R beta is also a component of the IL-22 receptor complex consisting of the IL-10 R beta chain and IL-22 R, another type II cytokine receptor family member.

目次に戻る

Citations

1. IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling
   Authors: AA Obajemu, N Rao, KA Dilley, JM Vargas, F Sheikh, RP Donnelly, RS Shabman, EG Meissner, L Prokunina-, OO Onabajo
   J. Immunol., 2017;0(0):.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


2. Trisomy 21 consistently activates the interferon response
   Elife, 2016;5(0):.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


3. HCV infection selectively impairs type I but not type III IFN signaling.
   Authors: Chandra P, Bao L, Song K, Aboulnasr F, Baker D, Shores N, Wimley W, Liu S, Hagedorn C, Fuchs S, Wu T, Balart L, Dash S
   Am J Pathol, 2014;184(1):214-29.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


4. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.
   Authors: Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K
   Genes Immun., 2009;10(8):702-14.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


5. Biological activity of interleukins-28 and -29: comparison with type I interferons.
   Authors: Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M
   Cytokine, 2005;31(2):109-18.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


6. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2.
   Authors: Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV, Anantha S, Dickensheets H, Dumoutier L, Renauld JC, Zdanov A, Donnelly RP, Kotenko SV
   J. Immunol., 2004;172(4):2006-10.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


7. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.
   Authors: Heuze-Vourc'h N
   Cancer Res., 2003;63(4):766-70.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


8. IL-28, IL-29 and their class II cytokine receptor IL-28R.
   Authors: Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM
   Nat. Immunol., 2002;4(1):63-8.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut

目次に戻る